<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on 16 November 2026 at 9:08 AM by All in One SEO v5.0.5 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://mendura.in/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Mendura Academic Innovators</title>
		<link><![CDATA[https://mendura.in]]></link>
		<description><![CDATA[Mendura Academic Innovators]]></description>
		<lastBuildDate><![CDATA[Mon, 16 Nov 2026 00:52:20 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://mendura.in/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://mendura.in/quizzes/instructor-led-pv-training/]]></guid>
			<link><![CDATA[https://mendura.in/quizzes/instructor-led-pv-training/]]></link>
			<title>Assessment_Instructor-led PV Training</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:52:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-practice-is-recommended-to-improve-completeness-and-accuracy-of-adr-reporting/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-practice-is-recommended-to-improve-completeness-and-accuracy-of-adr-reporting/]]></link>
			<title>Which practice is recommended to improve completeness and accuracy of ADR reporting?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:52:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/what-is-the-purpose-of-continuous-monitoring-and-feedback-in-pharmacovigilance/]]></guid>
			<link><![CDATA[https://mendura.in/questions/what-is-the-purpose-of-continuous-monitoring-and-feedback-in-pharmacovigilance/]]></link>
			<title>What is the purpose of continuous monitoring and feedback in pharmacovigilance?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:50:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/why-is-global-collaboration-important-in-pharmacovigilance/]]></guid>
			<link><![CDATA[https://mendura.in/questions/why-is-global-collaboration-important-in-pharmacovigilance/]]></link>
			<title>Why is global collaboration important in pharmacovigilance?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:48:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/who-is-described-as-the-first-point-of-contact-for-patients-in-the-distributor-pharmacist-role-slide/]]></guid>
			<link><![CDATA[https://mendura.in/questions/who-is-described-as-the-first-point-of-contact-for-patients-in-the-distributor-pharmacist-role-slide/]]></link>
			<title>Who is described as the first point of contact for patients in the distributor/pharmacist role slide?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:47:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-challenge-and-solution-pairing-is-correct/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-challenge-and-solution-pairing-is-correct/]]></link>
			<title>Which challenge-and-solution pairing is CORRECT?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:46:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/a-company-identifies-a-potential-safety-signal-which-actions-are-consistent-with-the-risk-management-slide/]]></guid>
			<link><![CDATA[https://mendura.in/questions/a-company-identifies-a-potential-safety-signal-which-actions-are-consistent-with-the-risk-management-slide/]]></link>
			<title>A company identifies a potential safety signal. Which actions are consistent with the risk-management slide?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:45:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-reaction-is-given-as-an-example-of-a-severe-adr/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-reaction-is-given-as-an-example-of-a-severe-adr/]]></link>
			<title>Which reaction is given as an example of a severe ADR?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:43:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-of-the-following-is-listed-as-an-mah-responsibility/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-of-the-following-is-listed-as-an-mah-responsibility/]]></link>
			<title>Which of the following is listed as an MAH responsibility?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:43:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/several-similar-allergic-reaction-reports-are-received-after-use-of-an-antibiotic-what-may-happen-when-multiple-similar-reports-are-recognized/]]></guid>
			<link><![CDATA[https://mendura.in/questions/several-similar-allergic-reaction-reports-are-received-after-use-of-an-antibiotic-what-may-happen-when-multiple-similar-reports-are-recognized/]]></link>
			<title>Several similar allergic-reaction reports are received after use of an antibiotic. What may happen when multiple similar reports are recognized?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:42:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-of-these-is-identified-as-a-source-of-adr-information/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-of-these-is-identified-as-a-source-of-adr-information/]]></link>
			<title>Which of these is identified as a source of ADR information?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:40:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-document-is-specifically-described-as-being-maintained-by-the-mah-as-part-of-its-pv-system/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-document-is-specifically-described-as-being-maintained-by-the-mah-as-part-of-its-pv-system/]]></link>
			<title>Which document is specifically described as being maintained by the MAH as part of its PV system?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:39:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/a-local-pv-contact-receives-an-adr-report-which-set-of-actions-best-matches-the-local-pv-personnel-responsibilities-in-the-presentation/]]></guid>
			<link><![CDATA[https://mendura.in/questions/a-local-pv-contact-receives-an-adr-report-which-set-of-actions-best-matches-the-local-pv-personnel-responsibilities-in-the-presentation/]]></link>
			<title>A local PV contact receives an ADR report. Which set of actions best matches the local PV personnel responsibilities in the presentation?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:39:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/what-is-the-stated-reporting-timeline-for-serious-adrs-in-the-sfda-requirements-slide/]]></guid>
			<link><![CDATA[https://mendura.in/questions/what-is-the-stated-reporting-timeline-for-serious-adrs-in-the-sfda-requirements-slide/]]></link>
			<title>What is the stated reporting timeline for serious ADRs in the SFDA requirements slide?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:38:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/what-is-the-role-of-meddra-in-the-pv-process-described/]]></guid>
			<link><![CDATA[https://mendura.in/questions/what-is-the-role-of-meddra-in-the-pv-process-described/]]></link>
			<title>What is the role of MedDRA in the PV process described?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:37:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/a-safety-database-contains-reports-describing-similar-reactions-what-is-the-next-activity-described-under-signal-detection-and-evaluation/]]></guid>
			<link><![CDATA[https://mendura.in/questions/a-safety-database-contains-reports-describing-similar-reactions-what-is-the-next-activity-described-under-signal-detection-and-evaluation/]]></link>
			<title>A safety database contains reports describing similar reactions. What is the next activity described under signal detection and evaluation?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:33:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-group-is-identified-as-a-frontline-source-for-detecting-and-reporting-adverse-events/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-group-is-identified-as-a-frontline-source-for-detecting-and-reporting-adverse-events/]]></link>
			<title>Which group is identified as a frontline source for detecting and reporting adverse events?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:20:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-sequence-most-closely-reflects-the-pv-workflow-shown-in-the-presentation/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-sequence-most-closely-reflects-the-pv-workflow-shown-in-the-presentation/]]></link>
			<title>Which sequence most closely reflects the PV workflow shown in the presentation?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:18:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/why-does-the-presentation-emphasize-accurate-and-complete-documentation-of-patient-drug-reaction-timing-and-outcome-details/]]></guid>
			<link><![CDATA[https://mendura.in/questions/why-does-the-presentation-emphasize-accurate-and-complete-documentation-of-patient-drug-reaction-timing-and-outcome-details/]]></link>
			<title>Why does the presentation emphasize accurate and complete documentation of patient, drug, reaction, timing and outcome details?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:17:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/what-does-faers-stand-for-in-the-pharmacovigilance/]]></guid>
			<link><![CDATA[https://mendura.in/questions/what-does-faers-stand-for-in-the-pharmacovigilance/]]></link>
			<title>What does FAERS stand for in the Pharmacovigilance?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:15:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-organisation-is-associated-with-good-pharmacovigilance-practices-gvp-modules-in-the-global-framework-slide/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-organisation-is-associated-with-good-pharmacovigilance-practices-gvp-modules-in-the-global-framework-slide/]]></link>
			<title>Which organisation is associated with Good Pharmacovigilance Practices (GVP) modules in the global framework slide?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:14:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/a-patient-reports-an-unusual-symptom-after-starting-a-medicine-the-pharmacist-is-unsure-whether-the-medicine-caused-it-what-should-happen-based-on-the-presentation/]]></guid>
			<link><![CDATA[https://mendura.in/questions/a-patient-reports-an-unusual-symptom-after-starting-a-medicine-the-pharmacist-is-unsure-whether-the-medicine-caused-it-what-should-happen-based-on-the-presentation/]]></link>
			<title>A patient reports an unusual symptom after starting a medicine. The pharmacist is unsure whether the medicine caused it. What should happen based on the presentation?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:13:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-of-the-following-is-listed-as-a-mild-adr-example/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-of-the-following-is-listed-as-a-mild-adr-example/]]></link>
			<title>Which of the following is listed as a mild ADR example?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:11:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/which-statement-best-distinguishes-an-adverse-event-ae-from-an-adverse-drug-reaction-adr-as-described-in-the-presentation/]]></guid>
			<link><![CDATA[https://mendura.in/questions/which-statement-best-distinguishes-an-adverse-event-ae-from-an-adverse-drug-reaction-adr-as-described-in-the-presentation/]]></link>
			<title>Which statement best distinguishes an adverse event (AE) from an adverse drug reaction (ADR), as described in the presentation?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:10:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/a-distributor-receives-several-complaints-of-rash-from-different-pharmacies-but-forwards-them-to-the-mah-several-weeks-later-according-to-the-training-case-study-what-is-the-key-pv-concern/]]></guid>
			<link><![CDATA[https://mendura.in/questions/a-distributor-receives-several-complaints-of-rash-from-different-pharmacies-but-forwards-them-to-the-mah-several-weeks-later-according-to-the-training-case-study-what-is-the-key-pv-concern/]]></link>
			<title>A distributor receives several complaints of rash from different pharmacies but forwards them to the MAH several weeks later. According to the training case study, what is the key PV concern?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:08:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/questions/what-is-the-primary-purpose-of-pharmacovigilance/]]></guid>
			<link><![CDATA[https://mendura.in/questions/what-is-the-primary-purpose-of-pharmacovigilance/]]></link>
			<title>What is the primary purpose of pharmacovigilance?</title>
			<pubDate><![CDATA[Mon, 16 Nov 2026 00:07:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/events/one-day-online-experiential-training-on-ectd-submission-for-gcc/]]></guid>
			<link><![CDATA[https://mendura.in/events/one-day-online-experiential-training-on-ectd-submission-for-gcc/]]></link>
			<title>One-Day Online Experiential Training on eCTD Submission for GCC</title>
			<pubDate><![CDATA[Wed, 08 Jul 2026 14:53:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/courses-2/regulatory-affairs-training/]]></guid>
			<link><![CDATA[https://mendura.in/courses-2/regulatory-affairs-training/]]></link>
			<title>Regulatory Affairs Training</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:39:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_9-product-renewal/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_9-product-renewal/]]></link>
			<title>RM_RA_9: Product Renewal</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:39:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_8-product-withdrawal/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_8-product-withdrawal/]]></link>
			<title>RM_RA_8: Product Withdrawal</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:39:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_7-overview-of-variations-in-uae-regulatory-affairs/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_7-overview-of-variations-in-uae-regulatory-affairs/]]></link>
			<title>RM_RA_7: Overview of Variations in UAE Regulatory Affairs</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:37:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_6-gsl-herbal-and-medical-device-registration/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_6-gsl-herbal-and-medical-device-registration/]]></link>
			<title>RM_RA_6: GSL, Herbal, and Medical Device Registration</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:35:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_5-conventional-medical-registration/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_5-conventional-medical-registration/]]></link>
			<title>RM_RA_5: Conventional Medical Registration</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:35:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_4-product-registration/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_4-product-registration/]]></link>
			<title>RM_RA_4: Product Registration</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:34:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_3-mah-site-registration-in-regulatory-affairs/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_3-mah-site-registration-in-regulatory-affairs/]]></link>
			<title>RM_RA_3: MAH &#038; Site Registration in Regulatory Affairs</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:33:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_2-product-classification-in-regulatory-affairs/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_2-product-classification-in-regulatory-affairs/]]></link>
			<title>RM_RA_2: Product Classification in Regulatory Affairs</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:32:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_ra_1introduction-to-regulatory-affairs/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_ra_1introduction-to-regulatory-affairs/]]></link>
			<title>RM_RA_1:Introduction to Regulatory Affairs</title>
			<pubDate><![CDATA[Wed, 13 May 2026 04:30:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/courses-2/advanced-pv-for-gcc/]]></guid>
			<link><![CDATA[https://mendura.in/courses-2/advanced-pv-for-gcc/]]></link>
			<title>Advanced PV Training for GCC</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:43:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_14-meddra-in-pharmacovigilance/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_14-meddra-in-pharmacovigilance/]]></link>
			<title>RM_PV_GCC_14: MedDRA in Pharmacovigilance</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:43:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_13-key-global-pharmacovigilance-tools/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_13-key-global-pharmacovigilance-tools/]]></link>
			<title>RM_PV_GCC_13: Key Global Pharmacovigilance Tools</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:42:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_12-risk-minimization-measures/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_12-risk-minimization-measures/]]></link>
			<title>RM_PV_GCC_12: Risk Minimization Measures</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:41:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_11-safety-communication/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_11-safety-communication/]]></link>
			<title>RM_PV_GCC_11: Safety Communication</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:39:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_10-signal-management/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_10-signal-management/]]></link>
			<title>RM_PV_GCC_10: Signal Management</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:39:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_9-post-authorization-safety-studies-pass/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_9-post-authorization-safety-studies-pass/]]></link>
			<title>RM_PV_GCC_9: Post-Authorization Safety Studies (PASS)</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:38:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_8-psur-pbrer/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_8-psur-pbrer/]]></link>
			<title>RM_PV_GCC_8: PSUR / PBRER</title>
			<pubDate><![CDATA[Sat, 09 May 2026 17:37:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_7-collection-management-and-submission-of-reports-of-suspected-adverse-reactions/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_7-collection-management-and-submission-of-reports-of-suspected-adverse-reactions/]]></link>
			<title>RM_PV_GCC_7: Collection, Management, and Submission of Reports of Suspected Adverse Reactions</title>
			<pubDate><![CDATA[Thu, 07 May 2026 06:26:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_6-risk-management-systems/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_6-risk-management-systems/]]></link>
			<title>RM_PV_GCC_6: Risk Management Systems</title>
			<pubDate><![CDATA[Thu, 07 May 2026 02:47:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/lessons/rm_pv_gcc_5-pharmacovigilance-audits/]]></guid>
			<link><![CDATA[https://mendura.in/lessons/rm_pv_gcc_5-pharmacovigilance-audits/]]></link>
			<title>RM_PV_GCC_5: Pharmacovigilance Audits</title>
			<pubDate><![CDATA[Thu, 07 May 2026 02:46:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/]]></guid>
			<link><![CDATA[https://mendura.in/]]></link>
			<title>Home Page</title>
			<pubDate><![CDATA[Thu, 23 Apr 2026 16:07:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://mendura.in/blog/]]></guid>
			<link><![CDATA[https://mendura.in/blog/]]></link>
			<title>Blog</title>
			<pubDate><![CDATA[Fri, 23 Oct 2015 07:47:25 +0000]]></pubDate>
		</item>
				</channel>
</rss>
